Palvella Therapeutics, Inc.

PVLA
$115.18 (+ $5.98 + 5.47%)
Last updated: 2026-05-20 21:09 UTC
PVLA Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS7207951036
CUSIP720795103
Market Price115.17
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-3.08
Market Cap$1.3B
Book Value3.49
Price to Book30.332
BetaN/A
52w High114.69
52w Low11.17
Next Earnings DateN/A

Palvella Therapeutics, Inc. trades under ticker PVLA on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US7207951036, CUSIP 720795103.

About the Company
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Price History